EyePoint Pharmaceuticals announced that the first patient has been dosed in the global, phase 3 LUGANO clinical trial of Duravyu, formerly EYP-1901, as a treatment for wet age-related macular degeneration, according to a press release.
The company also plans to initiate a second phase 3 trial, LUCIA, by the end of the year.
“The initiation of the LUGANO and LUCIA phase 3 program is a major milestone for retina specialists,” Carl D. Regillo, MD, FACS, FASRS, chief of retina service at Wills Eye Hospital in Philadelphia and clinical trial investigator, (Read more...)